Loading…

Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter

Human cytochrome P450 2A6 (CYP2A6) metabolizes various clinically relevant compounds, including nicotine- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood. We investigated the role of the glucocorticoid receptor (GR) in transcriptional regula...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmacology 2008-02, Vol.73 (2), p.451-460
Main Authors: Onica, Tania, Nichols, Kathleen, Larin, Meghan, Ng, Lorraine, Maslen, Ann, Dvorak, Zdenek, Pascussi, Jean-Marc, Vilarem, Marie-Josée, Maurel, Patrick, Kirby, Gordon M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093
cites cdi_FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093
container_end_page 460
container_issue 2
container_start_page 451
container_title Molecular pharmacology
container_volume 73
creator Onica, Tania
Nichols, Kathleen
Larin, Meghan
Ng, Lorraine
Maslen, Ann
Dvorak, Zdenek
Pascussi, Jean-Marc
Vilarem, Marie-Josée
Maurel, Patrick
Kirby, Gordon M
description Human cytochrome P450 2A6 (CYP2A6) metabolizes various clinically relevant compounds, including nicotine- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood. We investigated the role of the glucocorticoid receptor (GR) in transcriptional regulation of CYP2A6. Dexamethasone (DEX) increased CYP2A6 mRNA and protein levels in human hepatocytes in primary culture. This effect was attenuated by the GR receptor antagonist mifepristone (RU486; 17beta-hydroxy-11beta-[4-dimethylamino phenyl]-17alpha-[1-propynyl]estra-4,9-dien-3-one), suggesting that induction of CYP2A6 by DEX was mediated by the GR. In gene reporter assays, DEX caused dose-dependent increases in luciferase activity that was also prevented by RU486 and progressive truncations of the CYP2A6 promoter delineated DEX-responsiveness to a -95 to +12 region containing an hepatic nuclear factor 4 (HNF4) alpha response element (HNF4-RE). Mutation of the HNF4-RE abrogated HNF4alpha- and DEX-mediated transactivation of CYP2A6. In addition, overexpression of HNF4alpha increased CYP2A6 transcriptional activity by 3-fold. DEX increased HNF4alpha mRNA levels by 4-fold; however, the amount of HNF4alpha nuclear protein was unaltered. Electrophoretic mobility shift, chromatin immunoprecipitation (ChIP), and streptavidin DNA binding assays revealed that DEX increased binding of HNF4alpha to the HNF4-RE and that an interaction of GR and HNF4alpha occurred at this site. Moreover, ChIP assays indicated that histone H4 acetylation of the CYP2A6 proximal promoter chromatin was increased by DEX that may allow for increased binding of HNF4alpha to the HNF4-RE in human hepatocytes. These findings indicate that increased expression of CYP2A6 by DEX is mediated by the GR via a nonconventional transcriptional mechanism involving interaction of HNF4alpha with an HNF4-RE rather than a glucocorticoid response element.
doi_str_mv 10.1124/mol.107.039354
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70240732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20529693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093</originalsourceid><addsrcrecordid>eNqFkctu1DAUQC0EokNhyxJ5xS6DX4njZTU8pUrtgkplFd04NzNGThxspyq_xFfi6YzEkpWvpeNjXR1C3nK25VyoD1PwW870lkkja_WMbHgteMU458_JhjHRVK2p7y_Iq5R-MsZV3bKX5IJro1vemA358xEfYcJ8gBRmrCYcHGQc6LpUEferh-zCTMNID-sEM939uBVXDXXzQ_APmGg-IN371QYbYnY2uIFGtLjkECnMQwFtREhF2Lt5cPP-SYVL0Vo6r9YjRDqCPfKKgl8OQHN40i4xPLoJ_HGYQsb4mrwYwSd8cz4vyd3nT993X6vrmy_fdlfXlZVC5YqP1mgF1loBnEmlh0GDBN4KZKNk9WiVaEfshTJNa6FcG932GowSfWuZkZfk_clbPv61Ysrd5JJF72HGsKZOM6GYluK_oGC1MI2RBdyeQBtDShHHbolltfi746w7ZuxKxjLr7pSxPHh3Nq99SfIPP3eTfwHmGJyr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20529693</pqid></control><display><type>article</type><title>Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter</title><source>Free Full-Text Journals in Chemistry</source><creator>Onica, Tania ; Nichols, Kathleen ; Larin, Meghan ; Ng, Lorraine ; Maslen, Ann ; Dvorak, Zdenek ; Pascussi, Jean-Marc ; Vilarem, Marie-Josée ; Maurel, Patrick ; Kirby, Gordon M</creator><creatorcontrib>Onica, Tania ; Nichols, Kathleen ; Larin, Meghan ; Ng, Lorraine ; Maslen, Ann ; Dvorak, Zdenek ; Pascussi, Jean-Marc ; Vilarem, Marie-Josée ; Maurel, Patrick ; Kirby, Gordon M</creatorcontrib><description>Human cytochrome P450 2A6 (CYP2A6) metabolizes various clinically relevant compounds, including nicotine- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood. We investigated the role of the glucocorticoid receptor (GR) in transcriptional regulation of CYP2A6. Dexamethasone (DEX) increased CYP2A6 mRNA and protein levels in human hepatocytes in primary culture. This effect was attenuated by the GR receptor antagonist mifepristone (RU486; 17beta-hydroxy-11beta-[4-dimethylamino phenyl]-17alpha-[1-propynyl]estra-4,9-dien-3-one), suggesting that induction of CYP2A6 by DEX was mediated by the GR. In gene reporter assays, DEX caused dose-dependent increases in luciferase activity that was also prevented by RU486 and progressive truncations of the CYP2A6 promoter delineated DEX-responsiveness to a -95 to +12 region containing an hepatic nuclear factor 4 (HNF4) alpha response element (HNF4-RE). Mutation of the HNF4-RE abrogated HNF4alpha- and DEX-mediated transactivation of CYP2A6. In addition, overexpression of HNF4alpha increased CYP2A6 transcriptional activity by 3-fold. DEX increased HNF4alpha mRNA levels by 4-fold; however, the amount of HNF4alpha nuclear protein was unaltered. Electrophoretic mobility shift, chromatin immunoprecipitation (ChIP), and streptavidin DNA binding assays revealed that DEX increased binding of HNF4alpha to the HNF4-RE and that an interaction of GR and HNF4alpha occurred at this site. Moreover, ChIP assays indicated that histone H4 acetylation of the CYP2A6 proximal promoter chromatin was increased by DEX that may allow for increased binding of HNF4alpha to the HNF4-RE in human hepatocytes. These findings indicate that increased expression of CYP2A6 by DEX is mediated by the GR via a nonconventional transcriptional mechanism involving interaction of HNF4alpha with an HNF4-RE rather than a glucocorticoid response element.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.107.039354</identifier><identifier>PMID: 17978169</identifier><language>eng</language><publisher>United States</publisher><subject>Aryl Hydrocarbon Hydroxylases - biosynthesis ; Aryl Hydrocarbon Hydroxylases - genetics ; Cells, Cultured ; Cytochrome P-450 CYP2A6 ; Dexamethasone - pharmacology ; Enzyme Induction - drug effects ; Enzyme Induction - physiology ; HeLa Cells ; Hepatocyte Nuclear Factor 4 - genetics ; Hepatocyte Nuclear Factor 4 - metabolism ; Hepatocytes - drug effects ; Hepatocytes - metabolism ; Humans ; Mixed Function Oxygenases - biosynthesis ; Mixed Function Oxygenases - genetics ; Promoter Regions, Genetic - drug effects ; Promoter Regions, Genetic - physiology ; Protein Binding - drug effects ; Protein Binding - physiology ; Receptors, Glucocorticoid - genetics ; Receptors, Glucocorticoid - metabolism ; Up-Regulation - drug effects ; Up-Regulation - physiology</subject><ispartof>Molecular pharmacology, 2008-02, Vol.73 (2), p.451-460</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093</citedby><cites>FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17978169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onica, Tania</creatorcontrib><creatorcontrib>Nichols, Kathleen</creatorcontrib><creatorcontrib>Larin, Meghan</creatorcontrib><creatorcontrib>Ng, Lorraine</creatorcontrib><creatorcontrib>Maslen, Ann</creatorcontrib><creatorcontrib>Dvorak, Zdenek</creatorcontrib><creatorcontrib>Pascussi, Jean-Marc</creatorcontrib><creatorcontrib>Vilarem, Marie-Josée</creatorcontrib><creatorcontrib>Maurel, Patrick</creatorcontrib><creatorcontrib>Kirby, Gordon M</creatorcontrib><title>Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter</title><title>Molecular pharmacology</title><addtitle>Mol Pharmacol</addtitle><description>Human cytochrome P450 2A6 (CYP2A6) metabolizes various clinically relevant compounds, including nicotine- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood. We investigated the role of the glucocorticoid receptor (GR) in transcriptional regulation of CYP2A6. Dexamethasone (DEX) increased CYP2A6 mRNA and protein levels in human hepatocytes in primary culture. This effect was attenuated by the GR receptor antagonist mifepristone (RU486; 17beta-hydroxy-11beta-[4-dimethylamino phenyl]-17alpha-[1-propynyl]estra-4,9-dien-3-one), suggesting that induction of CYP2A6 by DEX was mediated by the GR. In gene reporter assays, DEX caused dose-dependent increases in luciferase activity that was also prevented by RU486 and progressive truncations of the CYP2A6 promoter delineated DEX-responsiveness to a -95 to +12 region containing an hepatic nuclear factor 4 (HNF4) alpha response element (HNF4-RE). Mutation of the HNF4-RE abrogated HNF4alpha- and DEX-mediated transactivation of CYP2A6. In addition, overexpression of HNF4alpha increased CYP2A6 transcriptional activity by 3-fold. DEX increased HNF4alpha mRNA levels by 4-fold; however, the amount of HNF4alpha nuclear protein was unaltered. Electrophoretic mobility shift, chromatin immunoprecipitation (ChIP), and streptavidin DNA binding assays revealed that DEX increased binding of HNF4alpha to the HNF4-RE and that an interaction of GR and HNF4alpha occurred at this site. Moreover, ChIP assays indicated that histone H4 acetylation of the CYP2A6 proximal promoter chromatin was increased by DEX that may allow for increased binding of HNF4alpha to the HNF4-RE in human hepatocytes. These findings indicate that increased expression of CYP2A6 by DEX is mediated by the GR via a nonconventional transcriptional mechanism involving interaction of HNF4alpha with an HNF4-RE rather than a glucocorticoid response element.</description><subject>Aryl Hydrocarbon Hydroxylases - biosynthesis</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Cells, Cultured</subject><subject>Cytochrome P-450 CYP2A6</subject><subject>Dexamethasone - pharmacology</subject><subject>Enzyme Induction - drug effects</subject><subject>Enzyme Induction - physiology</subject><subject>HeLa Cells</subject><subject>Hepatocyte Nuclear Factor 4 - genetics</subject><subject>Hepatocyte Nuclear Factor 4 - metabolism</subject><subject>Hepatocytes - drug effects</subject><subject>Hepatocytes - metabolism</subject><subject>Humans</subject><subject>Mixed Function Oxygenases - biosynthesis</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Promoter Regions, Genetic - drug effects</subject><subject>Promoter Regions, Genetic - physiology</subject><subject>Protein Binding - drug effects</subject><subject>Protein Binding - physiology</subject><subject>Receptors, Glucocorticoid - genetics</subject><subject>Receptors, Glucocorticoid - metabolism</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - physiology</subject><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkctu1DAUQC0EokNhyxJ5xS6DX4njZTU8pUrtgkplFd04NzNGThxspyq_xFfi6YzEkpWvpeNjXR1C3nK25VyoD1PwW870lkkja_WMbHgteMU458_JhjHRVK2p7y_Iq5R-MsZV3bKX5IJro1vemA358xEfYcJ8gBRmrCYcHGQc6LpUEferh-zCTMNID-sEM939uBVXDXXzQ_APmGg-IN371QYbYnY2uIFGtLjkECnMQwFtREhF2Lt5cPP-SYVL0Vo6r9YjRDqCPfKKgl8OQHN40i4xPLoJ_HGYQsb4mrwYwSd8cz4vyd3nT993X6vrmy_fdlfXlZVC5YqP1mgF1loBnEmlh0GDBN4KZKNk9WiVaEfshTJNa6FcG932GowSfWuZkZfk_clbPv61Ysrd5JJF72HGsKZOM6GYluK_oGC1MI2RBdyeQBtDShHHbolltfi746w7ZuxKxjLr7pSxPHh3Nq99SfIPP3eTfwHmGJyr</recordid><startdate>200802</startdate><enddate>200802</enddate><creator>Onica, Tania</creator><creator>Nichols, Kathleen</creator><creator>Larin, Meghan</creator><creator>Ng, Lorraine</creator><creator>Maslen, Ann</creator><creator>Dvorak, Zdenek</creator><creator>Pascussi, Jean-Marc</creator><creator>Vilarem, Marie-Josée</creator><creator>Maurel, Patrick</creator><creator>Kirby, Gordon M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>200802</creationdate><title>Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter</title><author>Onica, Tania ; Nichols, Kathleen ; Larin, Meghan ; Ng, Lorraine ; Maslen, Ann ; Dvorak, Zdenek ; Pascussi, Jean-Marc ; Vilarem, Marie-Josée ; Maurel, Patrick ; Kirby, Gordon M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aryl Hydrocarbon Hydroxylases - biosynthesis</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Cells, Cultured</topic><topic>Cytochrome P-450 CYP2A6</topic><topic>Dexamethasone - pharmacology</topic><topic>Enzyme Induction - drug effects</topic><topic>Enzyme Induction - physiology</topic><topic>HeLa Cells</topic><topic>Hepatocyte Nuclear Factor 4 - genetics</topic><topic>Hepatocyte Nuclear Factor 4 - metabolism</topic><topic>Hepatocytes - drug effects</topic><topic>Hepatocytes - metabolism</topic><topic>Humans</topic><topic>Mixed Function Oxygenases - biosynthesis</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Promoter Regions, Genetic - drug effects</topic><topic>Promoter Regions, Genetic - physiology</topic><topic>Protein Binding - drug effects</topic><topic>Protein Binding - physiology</topic><topic>Receptors, Glucocorticoid - genetics</topic><topic>Receptors, Glucocorticoid - metabolism</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onica, Tania</creatorcontrib><creatorcontrib>Nichols, Kathleen</creatorcontrib><creatorcontrib>Larin, Meghan</creatorcontrib><creatorcontrib>Ng, Lorraine</creatorcontrib><creatorcontrib>Maslen, Ann</creatorcontrib><creatorcontrib>Dvorak, Zdenek</creatorcontrib><creatorcontrib>Pascussi, Jean-Marc</creatorcontrib><creatorcontrib>Vilarem, Marie-Josée</creatorcontrib><creatorcontrib>Maurel, Patrick</creatorcontrib><creatorcontrib>Kirby, Gordon M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onica, Tania</au><au>Nichols, Kathleen</au><au>Larin, Meghan</au><au>Ng, Lorraine</au><au>Maslen, Ann</au><au>Dvorak, Zdenek</au><au>Pascussi, Jean-Marc</au><au>Vilarem, Marie-Josée</au><au>Maurel, Patrick</au><au>Kirby, Gordon M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter</atitle><jtitle>Molecular pharmacology</jtitle><addtitle>Mol Pharmacol</addtitle><date>2008-02</date><risdate>2008</risdate><volume>73</volume><issue>2</issue><spage>451</spage><epage>460</epage><pages>451-460</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>Human cytochrome P450 2A6 (CYP2A6) metabolizes various clinically relevant compounds, including nicotine- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood. We investigated the role of the glucocorticoid receptor (GR) in transcriptional regulation of CYP2A6. Dexamethasone (DEX) increased CYP2A6 mRNA and protein levels in human hepatocytes in primary culture. This effect was attenuated by the GR receptor antagonist mifepristone (RU486; 17beta-hydroxy-11beta-[4-dimethylamino phenyl]-17alpha-[1-propynyl]estra-4,9-dien-3-one), suggesting that induction of CYP2A6 by DEX was mediated by the GR. In gene reporter assays, DEX caused dose-dependent increases in luciferase activity that was also prevented by RU486 and progressive truncations of the CYP2A6 promoter delineated DEX-responsiveness to a -95 to +12 region containing an hepatic nuclear factor 4 (HNF4) alpha response element (HNF4-RE). Mutation of the HNF4-RE abrogated HNF4alpha- and DEX-mediated transactivation of CYP2A6. In addition, overexpression of HNF4alpha increased CYP2A6 transcriptional activity by 3-fold. DEX increased HNF4alpha mRNA levels by 4-fold; however, the amount of HNF4alpha nuclear protein was unaltered. Electrophoretic mobility shift, chromatin immunoprecipitation (ChIP), and streptavidin DNA binding assays revealed that DEX increased binding of HNF4alpha to the HNF4-RE and that an interaction of GR and HNF4alpha occurred at this site. Moreover, ChIP assays indicated that histone H4 acetylation of the CYP2A6 proximal promoter chromatin was increased by DEX that may allow for increased binding of HNF4alpha to the HNF4-RE in human hepatocytes. These findings indicate that increased expression of CYP2A6 by DEX is mediated by the GR via a nonconventional transcriptional mechanism involving interaction of HNF4alpha with an HNF4-RE rather than a glucocorticoid response element.</abstract><cop>United States</cop><pmid>17978169</pmid><doi>10.1124/mol.107.039354</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0026-895X
ispartof Molecular pharmacology, 2008-02, Vol.73 (2), p.451-460
issn 0026-895X
1521-0111
language eng
recordid cdi_proquest_miscellaneous_70240732
source Free Full-Text Journals in Chemistry
subjects Aryl Hydrocarbon Hydroxylases - biosynthesis
Aryl Hydrocarbon Hydroxylases - genetics
Cells, Cultured
Cytochrome P-450 CYP2A6
Dexamethasone - pharmacology
Enzyme Induction - drug effects
Enzyme Induction - physiology
HeLa Cells
Hepatocyte Nuclear Factor 4 - genetics
Hepatocyte Nuclear Factor 4 - metabolism
Hepatocytes - drug effects
Hepatocytes - metabolism
Humans
Mixed Function Oxygenases - biosynthesis
Mixed Function Oxygenases - genetics
Promoter Regions, Genetic - drug effects
Promoter Regions, Genetic - physiology
Protein Binding - drug effects
Protein Binding - physiology
Receptors, Glucocorticoid - genetics
Receptors, Glucocorticoid - metabolism
Up-Regulation - drug effects
Up-Regulation - physiology
title Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A55%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexamethasone-mediated%20up-regulation%20of%20human%20CYP2A6%20involves%20the%20glucocorticoid%20receptor%20and%20increased%20binding%20of%20hepatic%20nuclear%20factor%204%20alpha%20to%20the%20proximal%20promoter&rft.jtitle=Molecular%20pharmacology&rft.au=Onica,%20Tania&rft.date=2008-02&rft.volume=73&rft.issue=2&rft.spage=451&rft.epage=460&rft.pages=451-460&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.107.039354&rft_dat=%3Cproquest_cross%3E20529693%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c324t-1fc974accc2a10347dd7a3a182e0f305fc428feb24968cafc4678b7a942b8c093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20529693&rft_id=info:pmid/17978169&rfr_iscdi=true